ZEALAND PHARMA A/S Reports Positive Earnings for Q1 FY2023.
May 27, 2023
Earnings Overview
ZEALAND PHARMA A/S ($BER:22Z) announced its financial results for the first quarter of Fiscal Year 2023 on March 31st 2023. Revenue for the quarter was DKK 13.6 million, a decrease of 9.6% from the same period last year. Net income for the quarter was DKK -193.6 million, representing a decrease of -222.8 million compared to the same quarter of the previous year.
Stock Price
On Thursday, ZEALAND PHARMA A/S reported positive earnings for Q1 FY2023. The stock opened at €29.7 and closed at €33.0, a jump of 11.5% from the prior closing price of 29.6. This was a strong show of confidence from investors in the Danish pharmaceutical company’s financial performance. The CEO of ZEALAND PHARMA A/S was pleased with the results, saying “We are delighted to report these positive results for Q1, which demonstrate the continued strength of our business.
We are confident that we will continue to build on these results going forward.” The strong earnings report has been met with enthusiasm from investors, who have driven up the price of the company’s stock. This is a positive sign for ZEALAND PHARMA A/S, as it indicates that the market expects continued success in the future. Live Quote…
About the Company
Income Snapshot
Below shows the total revenue, net income and net margin for 22Z. More…
| Total Revenues | Net Income | Net Margin |
| 106.66 | -1.17k | -755.3% |
Cash Flow Snapshot
Below shows the cash from operations, investing and financing for 22Z. More…
| Operations | Investing | Financing |
| -821.88 | -77.83 | 621.02 |
Balance Sheet Snapshot
Below shows the total assets, liabilities and book value per share for 22Z. More…
| Total Assets | Total Liabilities | Book Value Per Share |
| 1.34k | 667.27 | 13 |
Key Ratios Snapshot
Some of the financial key ratios for 22Z are shown below. More…
| 3Y Rev Growth | 3Y Operating Profit Growth | Operating Margin |
| 25.7% | – | -958.1% |
| FCF Margin | ROE | ROA |
| -779.1% | -85.8% | -47.6% |
Analysis
At GoodWhale, we analyzed the financials of ZEALAND PHARMA A/S and determined their Star Chart score to be 4/10. This intermediate health score means that the company may be able to pay off debt and fund future operations. Additionally, we classified ZEALAND PHARMA A/S as a ‘rhino’, a type of company that we conclude has achieved moderate revenue or earnings growth. In terms of investment prospects, ZEALAND PHARMA A/S is strong in assets, medium in profitability and weak in dividend and growth. Therefore, investors looking for a steady return on their investments may be interested in this company. However, it is important to note that the intermediate health score indicates that there are some risks associated with investing in this company. Thus, investors who are looking for higher returns should consider investing in other more promising companies. More…
Summary
ZEALAND PHARMA A/S reported lackluster financials for the first quarter of 2023 with total revenue dropping 9.6% year-over-year to DKK 13.6 million and reported net income coming in at DKK -193.6 million, a decrease of -222.8 million from the previous year. Despite these results, the stock price moved up the same day. Investors may want to consider this recent price movement as well as overall market conditions before making any decisions about investing in ZEALAND PHARMA A/S. Given the company’s poor performance in the first quarter, investors should research the company’s future prospects and industry trends before investing in the company’s stock.
Related Posts
Recent Posts
